Brian Orelli

Novavax’s milestone means investors can now exhale.

Author Dr. Frank David breaks down what investors should look for when it comes to trial design.

Do some drug trial participants see improvements just because they’re told they might?

Positive clinical results should be a good thing, right?

Pfizer’s foreseeable future looks strong.

Trial design may matter more than you think.

What happens after a trial’s results are negative -- or positive?

Cutting-edge technology meets traditional healthcare.

By catering to the needs of medical professionals, Doximity could deliver in a big way.

This biotech company is showing early promise.